PRSS57 GENE EXPRESSION PREDICTS EARLY MOLECULAR RESPONSE  FAILURE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

Bozdağ Elif; Çetin Güven; Karaman Serap; Ünüvar Ayşegül; Karakaş Zeynep; Abacı Neslihan; Ekmekçi Sema

doi:https://dx.doi.org/10.26650/JARHS2024-1311348

Research Article

DOI :10.26650/JARHS2024-1311348 IUP :10.26650/JARHS2024-1311348 Full Text (PDF)

PRSS57 GENE EXPRESSION PREDICTS EARLY MOLECULAR RESPONSE FAILURE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

Elif Nur Bozdağ, Güven Çetin, Serap Karaman, Ayşegül Ünüvar, Zeynep Karakaş, Neslihan Abacı, Sema Sırma Ekmekçi

Objectives: The molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia (CML) is monitored by quantitative detection of BCR/ABL transcripts. After the initiation of the treatment, patients are followed-up with molecular analysis at three-month intervals. Early molecular response (EMR) is considered achieved when the BCR/ABL international scale (IS) is 10% or below in the three-month follow-up after treatment. This response, which has been reported to have a strong prognostic significance in CML patients, is associated with favorable longterm outcomes. However, the three-month follow-up period may be too long in terms of disease progression and treatment management for patients who fail to achieve EMR. Therefore, additional biomarkers that can predict the prognosis are needed.

Material and Methods: This study investigated the relationship between serine protease 57 (PRSS57) gene expression, and EMR. The PRSS57 gene expression in 20 CML patients was determined by the quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) method and its relationship with EMR was analyzed.

Results: The PRSS57 gene expression was found to be significantly higher in patients who failed EMR (p=0.002) and positively correlated with BCR/ ABL IS value (r=0.567, p=0.009). Our results also revealed that the PRSS57 gene expression was decreased in the post-treatment follow-up sample when compared with the diagnostic sample (p=0.000).

Conclusion: These findings indicate that the PRSS57 gene expression in diagnosis may be useful for predicting patients at high risk of EMR failure.

Keywords: CML, early molecular response, PRSS57

DOI :10.26650/JARHS2024-1311348 IUP :10.26650/JARHS2024-1311348 Full Text (PDF)

KRONİK MİYELOİD LÖSEMİLİ HASTALARDA ERKEN MOLEKÜLER YANIT TAHMİNİ İÇİN PRSS57 GEN İFADESİ

Elif Nur Bozdağ, Güven Çetin, Serap Karaman, Ayşegül Ünüvar, Zeynep Karakaş, Neslihan Abacı, Sema Sırma Ekmekçi

Amaç: Kronik myeloid lösemide (KML) tirozin kinaz inhibitörlerine verilen yanıtın moleküler takibi BCR/ABL transkriptlerine göre yapılmaktadır. Tedavi başlangıcından sonra hastalar üç aylık periyotlarla moleküler analizlerle takip edilmektedir. Tedavi sonrası üç aylık takipte BCR/ABL Uluslararası değeri (IS) %10 ve altına düştüğünde erken moleküler yanıt (EMY) başarılı kabul edilmektedir. KML hastalarında önemli prognostik değeri olduğu bildirilen bu yanıtın uzun vadede olumlu sonuçlarla ilişkili olduğu bulunmuştur. Ancak EMY başarısız olan hastalar için hastalığın ilerlemesi ve tedavi yönetimi için üç aylık takip geç olabilmektedir. Bu nedenle tanı sırasında prognozun tahmini sağlayabilecek ek biomarkerlara ihtiyaç duyulmaktadır.

Gereç ve Yöntemler: Çalışmamızda serin proteaz 57 (PRSS57) gen ifadesinin EMY ile ilişkisi araştırıldı. 20 KML hastasında PRSS57 gen ifadesi kantitatif ters transkriptaz polimeraz zincir reaksiyonu (qRT-PZR) yöntemiyle belirlendi ve EMY ile ilişkisi analiz edildi.

Bulgular: PRSS57 gen ifadesi EMY başarısız hastalarda anlamlı derecede yüksek olduğu (p=0,002) ve BCR/ABL IS değeri ile pozitif yönde bağlantılı olduğu bulundu. Sonuçlarımız aynı zamanda PRSS gen ifadesinin tedavi sonrası izlem örneklerinde azaldığını gösterdi.

Sonuç: Bu bulgular tanıda PRSS57 ifadesinin EMY başarısızlığı riski yüksek hastaların tahmininde yararlı olabileceğini göstermektedir.

Keywords: KML, erken moleküler yanıt, PRSS57

References

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Data, 8 Registries, Nov 2021 Sub (1975-2019) - Linked To County Attributes - Time Dependent (1990-2019) Income/ Rurality, 1969-2020 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2022, based on the November 2021 submission. google scholar
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022;72(1):7-33. google scholar
O’Dwyer M. Multifaceted approach to the treatment of bcr-abl-positive leukemias. Oncologist 2002;7 Suppl 1:30-8. google scholar
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020;34(4):966-84. google scholar
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology Chronic Myeloid Leukemia (Version 1.2023). Retrieved from https://www.nccn.org/professionals/ physician_gls/pdf/cml.pdf google scholar
Hehlmann R. The New ELN Recommendations for Treating CML. J Clin Med 2020;9(11):3671. google scholar
Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, et al. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020;18(10):1385-415. google scholar
Narlı Özdemir Z, Kılıçaslan NA, Yılmaz M, Eşkazan AE. Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities. Int J Hematol 2023;117(1):3-15. google scholar
Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349(15):1423-32. google scholar
Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108(1):28-37. google scholar
Jabbour E, Cortes JE, Kantarjian HM. Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications. Cancer 2008;112(10):2112-8. google scholar
Bhamidipati PK, Kantarjian H, Cortes J, Cornelison AM, Jabbour E. Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol 2013;4(2):103-17. google scholar
Cross NC, White HE, Müller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012;26(10):2172-5. google scholar
Harada I, Sasaki H, Murakami K, Nishiyama A, Nakabayashi J, Ichino M, et al. Compromised anti-tumor-immune features of myeloid cell components in chronic myeloid leukemia patients. Sci Rep 2021;11(1):18046. google scholar
Kok CH, Yeung DT, Lu L, Watkins DB, Leclercq TM, Dang P, et al. Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. Blood Adv 2019;3(10):1610-21. google scholar
Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G,et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014;123(9):1353-60. google scholar
Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27(35):6041-51. google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format

EXPORT

APA

Bozdağ, E.N., Çetin, G., Karaman, S., Ünüvar, A., Karakaş, Z., Abacı, N., & Ekmekçi, S.S. (2024). PRSS57 GENE EXPRESSION PREDICTS EARLY MOLECULAR RESPONSE FAILURE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA. Journal of Advanced Research in Health Sciences, 7(1), 32-36. https://doi.org/10.26650/JARHS2024-1311348

AMA

Bozdağ E N, Çetin G, Karaman S, Ünüvar A, Karakaş Z, Abacı N, Ekmekçi S S. PRSS57 GENE EXPRESSION PREDICTS EARLY MOLECULAR RESPONSE FAILURE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA. Journal of Advanced Research in Health Sciences. 2024;7(1):32-36. https://doi.org/10.26650/JARHS2024-1311348

ABNT

Bozdağ, E.N.; Çetin, G.; Karaman, S.; Ünüvar, A.; Karakaş, Z.; Abacı, N.; Ekmekçi, S.S. PRSS57 GENE EXPRESSION PREDICTS EARLY MOLECULAR RESPONSE FAILURE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA. Journal of Advanced Research in Health Sciences, [Publisher Location], v. 7, n. 1, p. 32-36, 2024.

Chicago: Author-Date Style

Bozdağ, Elif Nur, and Güven Çetin and Serap Karaman and Ayşegül Ünüvar and Zeynep Karakaş and Neslihan Abacı and Sema Sırma Ekmekçi. 2024. “PRSS57 GENE EXPRESSION PREDICTS EARLY MOLECULAR RESPONSE FAILURE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA.” Journal of Advanced Research in Health Sciences 7, no. 1: 32-36. https://doi.org/10.26650/JARHS2024-1311348

Chicago: Humanities Style

Bozdağ, Elif Nur, and Güven Çetin and Serap Karaman and Ayşegül Ünüvar and Zeynep Karakaş and Neslihan Abacı and Sema Sırma Ekmekçi. “PRSS57 GENE EXPRESSION PREDICTS EARLY MOLECULAR RESPONSE FAILURE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA.” Journal of Advanced Research in Health Sciences 7, no. 1 (Nov. 2024): 32-36. https://doi.org/10.26650/JARHS2024-1311348

Harvard: Australian Style

Bozdağ, EN & Çetin, G & Karaman, S & Ünüvar, A & Karakaş, Z & Abacı, N & Ekmekçi, SS 2024, 'PRSS57 GENE EXPRESSION PREDICTS EARLY MOLECULAR RESPONSE FAILURE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA', Journal of Advanced Research in Health Sciences, vol. 7, no. 1, pp. 32-36, viewed 15 Nov. 2024, https://doi.org/10.26650/JARHS2024-1311348

Harvard: Author-Date Style

Bozdağ, E.N. and Çetin, G. and Karaman, S. and Ünüvar, A. and Karakaş, Z. and Abacı, N. and Ekmekçi, S.S. (2024) ‘PRSS57 GENE EXPRESSION PREDICTS EARLY MOLECULAR RESPONSE FAILURE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA’, Journal of Advanced Research in Health Sciences, 7(1), pp. 32-36. https://doi.org/10.26650/JARHS2024-1311348 (15 Nov. 2024).

MLA

Bozdağ, Elif Nur, and Güven Çetin and Serap Karaman and Ayşegül Ünüvar and Zeynep Karakaş and Neslihan Abacı and Sema Sırma Ekmekçi. “PRSS57 GENE EXPRESSION PREDICTS EARLY MOLECULAR RESPONSE FAILURE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA.” Journal of Advanced Research in Health Sciences, vol. 7, no. 1, 2024, pp. 32-36. [Database Container], https://doi.org/10.26650/JARHS2024-1311348

Vancouver

Bozdağ EN, Çetin G, Karaman S, Ünüvar A, Karakaş Z, Abacı N, Ekmekçi SS. PRSS57 GENE EXPRESSION PREDICTS EARLY MOLECULAR RESPONSE FAILURE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA. Journal of Advanced Research in Health Sciences [Internet]. 15 Nov. 2024 [cited 15 Nov. 2024];7(1):32-36. Available from: https://doi.org/10.26650/JARHS2024-1311348 doi: 10.26650/JARHS2024-1311348

ISNAD

Bozdağ, ElifNur - Çetin, Güven - Karaman, Serap - Ünüvar, Ayşegül - Karakaş, Zeynep - Abacı, Neslihan - Ekmekçi, SemaSırma. “PRSS57 GENE EXPRESSION PREDICTS EARLY MOLECULAR RESPONSE FAILURE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA”. Journal of Advanced Research in Health Sciences 7/1 (Nov. 2024): 32-36. https://doi.org/10.26650/JARHS2024-1311348

Volume 7, Issue 12024, P. 32-36

TIMELINE

Submitted	08.06.2023
Accepted	11.10.2023
Published Online	08.02.2024

LICENCE

Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.

Journal of Advanced Research in Health Sciences